Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of multiple-dose NEPA for prevention of chemotherapy-induced nausea and vomiting during BEAM/FEAM conditioning
2015-003318-26Phase 2Completed
- Sponsor
- Associazione Angela Serra (Salento)
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palonosetron and netupitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Associazione Angela Serra (Salento). Primary endpoint: Complete response during conditioning chemotherapy regimen. Started Sep 2021; status: completed.
02
Drugs
palonosetronnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2015-003318-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003318-26.